Go to deals
Healthcare

York Instruments Ltd has acquired the MEG business of Elekta

York Instruments Ltd has acquired MEGIN, the MEG business of Elekta AB. Financial details have not been disclosed.

York Instruments is a company specializing in magnetic measurements and their healthcare applications. Using the very latest technologies and methodologies, York Instruments is focused on magnetoencephalography (MEG) and its ability to effectively assess neural networks. York Instruments' revolutionary MEG technology allows for earlier and improved diagnostic capability in relation to a variety of neurological diseases and conditions.

Magnetoencephalography (MEG) is the brain activity-mapping business of Elekta. MEG is a diagnostic functional neuroimaging technique for mapping brain activity. This can be applied in a clinical setting to find locations of abnormalities as well as in a research setting to simply measure brain activity. Elekta's MEG business, known as MEGIN, is a leading supplier of magnetoencephalography (MEG) technology, with more than 100 delivered MEG systems worldwide.

Elekta AB is a Swedish company that provides radiation therapy, radiosurgery, related equipment and clinical management for the treatment of cancer and brain disorders. The company employs 3,600 people around the world. Elekta is listed on NASDAQ Stockholm.

Oaklins Smith & Williamson, based in the UK, advised the buyer in this transaction.

Service
M&A buy-side
Parties

Talk to the deal team

 Brian  Livingston

Brian Livingston

Managing Director

London, United Kingdom
Oaklins Smith & Williamson
 Zach  Francis

Zach Francis

Associate

London, United Kingdom
Oaklins Smith & Williamson

Related deals

Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Learn more
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Learn more